Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening

被引:0
|
作者
Abedellatif, Saif-Eldin [1 ]
Hosni, Racha [1 ]
Waha, Andreas [2 ]
Gielen, Gerrit H. [2 ]
Banat, Mohammed [3 ]
Hamed, Motaz [3 ]
Gueresir, Erdem [3 ]
Froehlich, Anne [4 ]
Sirokay, Judith [4 ]
Wulf, Anna-Lena [1 ]
Kristiansen, Glen [1 ]
Pietsch, Torsten [2 ]
Vatter, Hartmut [3 ]
Hoelzel, Michael [5 ]
Schneider, Matthias [3 ]
Toma, Marieta Ioana [1 ]
机构
[1] Univ Hosp Bonn, Inst Pathol, D-53127 Bonn, Germany
[2] Univ Hosp Bonn, Inst Neuropathol, D-53127 Bonn, Germany
[3] Univ Hosp Bonn, Dept Neurosurg, D-53127 Bonn, Germany
[4] Univ Hosp Bonn, Dept Dermatol, D-53127 Bonn, Germany
[5] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
关键词
melanoma; brain metastases; BRAF; organoids; DABRAFENIB;
D O I
10.3390/pharmaceutics16081042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and aims: Brain metastases are prevalent in the late stages of malignant melanoma. Multimodal therapy remains challenging. Patient-derived organoids (PDOs) represent a valuable pre-clinical model, faithfully recapitulating key aspects of the original tumor, including the heterogeneity and the mutational status. This study aimed to establish PDOs from melanoma brain metastases (MBM-PDOs) and to test the feasibility of using them as a model for in vitro targeted-therapy drug testing. Methods: Surgical resection samples from eight patients with melanoma brain metastases were used to establish MBM-PDOs. The samples were enzymatically dissociated followed by seeding into low-attachment plates to generate floating organoids. The MBM-PDOs were characterized genetically, histologically, and immunohistologically and compared with the parental tissue. The MBM-PDO cultures were exposed to dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) followed by a cell viability assessment. Results: Seven out of eight cases were successfully cultivated, maintaining the histological, immunohistological phenotype, and the mutational status of the parental tumors. Five out of seven cases harbored BRAF V600E mutations and were responsive to BRAF and MEK inhibitors in vitro. Two out of seven cases were BRAF wild type: one case harboring an NRAS mutation and the other harboring a KIT mutation, and both were resistant to BRAF and MEK inhibitor therapy. Conclusions: We successfully established PDOs from melanoma brain metastases surgical specimens, which exhibited a consistent histological and mutational profile with the parental tissue. Using FDA-approved BRAF and MEK inhibitors, our data demonstrate the feasibility of employing MBM-PDOs for targeted-therapy in vitro testing.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] High-throughput screening of patient-derived HCC organoids for drug discovery
    Michelle, Alissa
    Wong, Go
    Cheung, Winnie
    Wong, Maggie
    Wong, Aikha
    Lam, Helena
    Zhang, Zhe
    Man, Matthew
    Chen, Hui
    Close, David
    Johnston, Paul
    Chan, Anthony
    Lai, Paul
    Kwong, Joseph
    Wong, Nathalie
    CANCER RESEARCH, 2020, 80 (16)
  • [22] Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids
    Wang, Zhiwei
    Guo, Yinghao
    Jin, Yun
    Zhang, Xiaoxiao
    Geng, Hao
    Xie, Guangyuan
    Ye, Dan
    Yu, Yuanquan
    Liu, Daren
    Zhou, Donger
    Li, Baizhou
    Luo, Yan
    Peng, Shuyou
    Li, Jiangtao
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [23] Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids
    Zhiwei Wang
    Yinghao Guo
    Yun Jin
    Xiaoxiao Zhang
    Hao Geng
    Guangyuan Xie
    Dan Ye
    Yuanquan Yu
    Daren Liu
    Donger Zhou
    Baizhou Li
    Yan Luo
    Shuyou Peng
    Jiangtao Li
    Cancer Cell International, 21
  • [24] Patient-derived parathyroid organoids as a tracer and drug-screening application model
    Noltes, Milou E.
    Sondorp, Luc H. J.
    Kracht, Laura
    Antunes, Ines F.
    Wardenaar, Rene
    Kelder, Wendy
    Kemper, Annelies
    Szymanski, Wiktor
    Zandee, Wouter T.
    Jansen, Liesbeth
    Brouwers, Adrienne H.
    Coppes, Robert P.
    Kruijff, Schelto
    STEM CELL REPORTS, 2022, 17 (11): : 2518 - 2530
  • [25] Patient-derived cancer organoids for drug screening: Basic technology and clinical application
    Ren, Xiaoxue
    Chen, Weikang
    Yang, Qingxia
    Li, Xiaoxing
    Xu, Lixia
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (08) : 1446 - 1454
  • [26] Correction: In vitro drug testing using patient-derived ovarian cancer organoids
    Lin-Yu Chen
    Yu-Ting Chou
    Phui-Ly Liew
    Ling-Hui Chu
    Kuo-Chang Wen
    Shiou-Fu Lin
    Yu-Chun Weng
    Hui-Chen Wang
    Po-Hsuan Su
    Hung-Cheng Lai
    Journal of Ovarian Research, 17 (1)
  • [27] Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
    Narasimhan, Vignesh
    Wright, Josephine A.
    Churchill, Michael
    Wang, Tongtong
    Rosati, Rachele
    Lannagan, Tamsin R. M.
    Vrbanac, Laura
    Richardson, Anne B.
    Kobayashi, Hiroki
    Price, Timothy
    Tye, Gayle X. Y.
    Marker, Julie
    Hewett, Peter J.
    Flood, Michael P.
    Pereira, Shalini
    Whitney, G. Adam
    Michael, Michael
    Tie, Jeanne
    Mukherjee, Siddhartha
    Grandori, Carla
    Heriot, Alexander G.
    Worthley, Daniel L.
    Ramsay, Robert G.
    Woods, Susan L.
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3662 - 3670
  • [28] Patient-Derived Organoids as an In Vitro Model of Neuroendocrine Tumors
    Liu, Iris H.
    Neal, James T.
    Zemek, Allison J.
    Kunz, Pamela L.
    Kuo, Calvin J.
    PANCREAS, 2016, 45 (03) : 467 - 467
  • [29] Patient-Derived Organoids as a Model for Cancer Drug Discovery
    Rae, Colin
    Amato, Francesco
    Braconi, Chiara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (07)
  • [30] Development of an Extracellular Matrix Plate for Drug Screening Using Patient-Derived Tumor Organoids
    Jung, Yong Hun
    Park, Kyungwon
    Kim, Minseop
    Oh, Hyunjik
    Choi, Dong-Hee
    Ahn, Jinchul
    Lee, Sat-byol
    Na, Kyuhwan
    Min, Byung Soh
    Kim, Jin-A.
    Chung, Seok
    BIOCHIP JOURNAL, 2023, 17 (2) : 284 - 292